$1.87 Billion in Sales Expected for The Clorox Company (NYSE:CLX) This Quarter

Brokerages expect The Clorox Company (NYSE:CLXGet Rating) to report sales of $1.87 billion for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Clorox’s earnings. The highest sales estimate is $1.89 billion and the lowest is $1.85 billion. Clorox posted sales of $1.80 billion during the same quarter last year, which suggests a positive year over year growth rate of 3.9%. The company is scheduled to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Clorox will report full-year sales of $7.18 billion for the current fiscal year, with estimates ranging from $7.16 billion to $7.19 billion. For the next fiscal year, analysts anticipate that the firm will post sales of $7.47 billion, with estimates ranging from $7.39 billion to $7.60 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Clorox.

Clorox (NYSE:CLXGet Rating) last released its quarterly earnings data on Monday, May 2nd. The company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.97 by $0.34. Clorox had a return on equity of 92.98% and a net margin of 6.44%. The business had revenue of $1.81 billion during the quarter, compared to analyst estimates of $1.81 billion. During the same quarter in the previous year, the firm posted $1.62 EPS.

CLX has been the topic of several recent analyst reports. The Goldman Sachs Group dropped their price target on Clorox from $145.00 to $127.00 in a research report on Tuesday, March 29th. Credit Suisse Group cut their price target on Clorox from $160.00 to $155.00 and set an “underperform” rating for the company in a report on Friday, February 4th. Barclays dropped their target price on Clorox from $126.00 to $115.00 and set an “underweight” rating for the company in a report on Monday. Wells Fargo & Company increased their price target on Clorox from $120.00 to $130.00 in a research report on Tuesday, May 3rd. Finally, StockNews.com initiated coverage on Clorox in a research report on Thursday, March 31st. They issued a “hold” rating on the stock. Ten investment analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Sell” and an average target price of $141.21.

In related news, COO Eric H. Reynolds sold 585 shares of the business’s stock in a transaction that occurred on Monday, May 9th. The shares were sold at an average price of $154.83, for a total value of $90,575.55. Following the completion of the transaction, the chief operating officer now directly owns 17,289 shares in the company, valued at approximately $2,676,855.87. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.58% of the stock is currently owned by company insiders.

Several large investors have recently made changes to their positions in the stock. Dark Forest Capital Management LP bought a new position in shares of Clorox during the third quarter valued at approximately $25,000. Eagle Bay Advisors LLC purchased a new stake in shares of Clorox during the third quarter valued at $26,000. Newbridge Financial Services Group Inc. boosted its stake in shares of Clorox by 185.2% during the fourth quarter. Newbridge Financial Services Group Inc. now owns 154 shares of the company’s stock valued at $27,000 after purchasing an additional 100 shares during the period. TAP Consulting LLC purchased a new stake in shares of Clorox during the fourth quarter valued at $27,000. Finally, FSB Premier Wealth Management Inc. purchased a new stake in shares of Clorox during the fourth quarter valued at $28,000. 77.28% of the stock is owned by hedge funds and other institutional investors.

CLX opened at $146.40 on Friday. Clorox has a one year low of $127.02 and a one year high of $191.75. The company has a debt-to-equity ratio of 3.28, a quick ratio of 0.40 and a current ratio of 0.71. The stock’s fifty day moving average is $145.41 and its 200-day moving average is $156.18. The company has a market capitalization of $18.02 billion, a PE ratio of 39.67, a P/E/G ratio of 4.74 and a beta of 0.18.

About Clorox (Get Rating)

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brand names; professional cleaning and disinfecting products under the CloroxPro, Clorox Healthcare, and Clorox Total 360 brand names; professional food service products under the Hidden Valley brand name; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brand names in the United States.

Read More

Get a free copy of the Zacks research report on Clorox (CLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.